Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FDA approves a new opioid 10 times more powerful than fentanyl https://www.statnews.com/pharmalot/2018/11/02/fda-dsuvia-fentanyl-approval/
HEMP, INC.’S STOCK BUY BACK PLAN Hemp, Inc.’s stock buy back is a mechanism to dramatically reduce the outstanding shares in the open market, as stated in Hemp, Inc.’s September 14, 2017 press release:
Hemp, Inc. executives are currently negotiating large sales of LCMs (lost circulation materials) to oil companies on five continents including a US-based company that is interested in buying the entire productive capacity of the company's LCMs and more. "If this deal comes to fruition, we will start running two, and then later three shifts, six days a week. We currently have 18,000,000 pounds of kenaf and hemp in inventory which translates into finished product that will be sold for $2 - $4 per pound. You can do the math," said Perlowin
Hemp, Inc. Announces Delivery of Advanced CBD Hemp Oil Extraction Post Processing Equipment
SPRING HOPE, NC--(Marketwired - Nov 2, 2017) - Hemp, Inc. (OTC PINK: HEMP), a global leader in the industrial hemp industry with the largest multi-purpose industrial hemp processing facility in the western hemisphere, announced today it has received all brand new, state-of-the-art components of the cannabidiol (CBD) post processing equipment to complete the Company's hemp oil extraction infrastructure (Division 2). The latest equipment additions to the Company's extraction operation will be assembled in the coming days.
"We chose the most cutting edge, state-of-the-art processing equipment on the market, from Across International, to ensure our CBD extracts lead the industry in quality and consistency, allowing us to bring innovative bulk CBD products to market. We have also partnered with Across International to display this state-of-the-art equipment at our Hemp University educational symposiums in the upcoming year. This equipment allows us to 'winterize' the raw CBD crude oil. After the CBD crude oil is winterized, we are able to perform the remaining post processing so that we can make an array of products, including but not limited to tinctures and cartridges to put it in vape pens... our options are limitless with this equipment," said David Schmitt, COO of Hemp, Inc.'s wholly owned subsidiary, Industrial Hemp Manufacturing, LLC.
In August, Hemp, Inc. announced the official launch of its NuAxon Tech CO2 Supercritical Extractor.
"The completion of our hemp oil extraction infrastructure will allow us to ramp up production of CBD products, creating increased Company value for the public and shareholders." said Hemp, Inc. CEO Bruce Perlowin. "The market price of CBD crystalline isolate was commonly $20,000 per kilogram at the early part of 2017. While prices have gone down this year, in some cases, to as low as $6,500 per kilo on the low end volume price, CBD full spectrum extract making customized formulas have in some cases gone up and other cases gone down. Whether the price decreases or increases, I think it's important to note and remind our shareholders that while we expect significant returns from our hemp oil extraction, it's a secondary component of our overall business plan that we added to 'enhance' our revenues. Hemp, Inc.'s primary business is focused on producing non-toxic loss circulation material (LCM) and spill absorbents for the oil and gas industries."
In oil or gas well drilling, "loss circulation" occurs when drilling fluid flows into one or more geological formations instead of returning up the annulus. "Loss circulation" can be a serious problem during the drilling of an oil well or gas well. Hemp, Inc., as mentioned in a previous press release, has a provisional patent that covers Hemp, Inc.'s process of dramatically reducing the time, cost, and energy required to create LCMs and spill absorbents using natural plant materials - resulting in a higher quality product for the oil and gas industries.
"Aside from our LCMs, we look forward to showcasing how our new, state-of-the-art post processing CBD equipment at our first 2018 Hemp University educational symposium. Our Hemp University educational symposiums have been an overwhelming success and they're growing. We had to stop selling tickets at the last symposium because we were over capacity. We originally planned for only 100 attendees but there were over 140 people in attendance. We're expecting the number of attendees to double at the next symposium, scheduled for December 2, 2017. Of course, we plan to hold it at a much larger venue. We strongly encourage you to buy your tickets early. We will definitely sell out and this isn't marketing hype," says Perlowin. "The hemp educational infrastructure we provide through 'The Hemp University' is delivering on our goal to make America great again by making America hemp again. We are teaching farmers, landowners, investors and entrepreneurs how to create a profitable income stream by maximizing their per-acre crop revenue."
As previously disclosed, TerraForm Power has been engaged in settlement discussions with SunEdison, Inc. (SunEdison) as part of its ongoing strategic alternatives process, and announced today that it has entered into a memorandum of understanding (the MOU) with SunEdison. The MOU outlines potential separate settlements of claims between SunEdison and the Company and SunEdison and TerraForm Global, Inc. (Nasdaq:GLBL) (TerraForm Global) in connection with the Chapter 11 bankruptcy case of SunEdison (the SunEdison Bankruptcy). The Companys Board of Directors approved the MOU upon the recommendation of its independent members who do not also serve on the Board of Directors of TerraForm Global. The settlements of the intercompany claims are subject to the approval of the U.S. bankruptcy court overseeing the SunEdison Chapter 11 cases.
The MOU contains certain non-binding proposed settlement terms to resolve the complex legal relationship between the Company and SunEdison, including, among other things, an allocation of the total consideration paid in connection with a transaction for all or part of TerraForm Power and, with certain exceptions, the full mutual release of all claims of SunEdison and its affiliated debtors and non-debtors. Under the proposed settlement terms, SunEdison would receive consideration equal to 36.9% of the total consideration paid to all of the Companys shareholders, reflecting the settlement of intercompany claims, cancelation of incentive distribution rights and other factors considered by the Companys Board of Directors. The remaining consideration would be distributed to holders of shares of the Class A common stock of the Company.
In addition, under the MOU, TerraForm Power and SunEdison will work toward the terms of an agreement for a sale of all or part of the Company, provided that the final settlement agreement is reached on or before January 27, 2017. Any transaction will be jointly approved by both TerraForm Power and SunEdison.
The proposed terms are not legally binding on any party to the MOU and are subject to a number of conditions and contingencies, including TerraForm Power entering into a transaction jointly approved by the Company and SunEdison, TerraForm Global entering into a transaction jointly approved by TerraForm Global and SunEdison and approval by the U.S. Bankruptcy Court by April 1, 2017 of the settlement agreements involving SunEdison and each of the Company
TerraForm Power and SunEdison will work toward the terms of an agreement for a sale of all or part of the Company, provided that the final settlement agreement is reached on or before January 27, 2017. Any transaction will be jointly approved by both TerraForm Power and SunEdison.
The proposed terms are not legally binding on any party to the MOU and are subject to a number of conditions and contingencies, including TerraForm Power entering into a transaction jointly approved by the Company and SunEdison, TerraForm Global entering into a transaction jointly approved by TerraForm Global and SunEdison and approval by the U.S. Bankruptcy Court by April 1, 2017 of the settlement agreements involving SunEdison and each of the Company and TerraForm Global.
hello, is that you letter?
We shareholders did not buy parts of SUNE or just the bankrupt part of SUNE,we bought a whole SUNE and paid a full price for it. They want to cancel us,but issue new shares to their buddies again. Thank You Honorable Judge Dalibor Dvanajscak
Shareholder concern Dalibor Dvanajscak to: bernstein.chambers 01/11/2017 03:00 PM Hide Details From: Dalibor Dvanajscak To: bernstein.chambers@nysb.uscourts.gov History: This message has been forwarded.
Page 1of 1
Tomorrow 10.00am
NYCTL 1998-2 TRUST Motion for Relief from Stay Tax lien on property located at 73-75 Avenue C, New York, NY 10009
16-10992-smb SunEdison, Inc., et al., Ch. 11
16-10992-smb SunEdison, Inc., et al., Ch. 11
Debtors' Motion to Approve Sale of Portion of Minnesota Projects to AES
Stricken from the calendar
http://www.nysb.uscourts.gov/calendars/smb.html
Brookfield Asset Management would purchase all of (SUNEQ)$1.50 looks good
Interesting still not Stock split or Nasdaq delist.Almost a year under $1 Nasdaq rule 180 days,How is that possible?
The Company is seeking customary authority from the Bankruptcy Court to continue to make wage and salary payments, continue various benefits for employees and honor certain customer programs, such as benefits earned under its myGSOM REWARDS loyalty program, gift cards and returns on merchandise purchased prior to the bankruptcy filing. Bankruptcy Court approval for those requests is expected within the next few days. As a result, the Company’s salaried and hourly employees should continue to be paid on the normal schedule, and there are expected to be no changes to various employee benefit programs. In addition, customers should not experience any changes in their relationship with PacSun as there are expected to be no changes to the customer loyalty program, warranty programs, return policies or gift card balances
Josh Olshansky, Managing Director at Golden Gate Capital, said: “PacSun has successfully transitioned beyond its historical base of action sports brands to what we believe is the most relevant and coveted mix of brands celebrating the California lifestyle. We believe in the future of the Company, as reflected by our significant injection of new capital into the business. While there is still work to be done, we are supportive of the steps the Company and its management team have taken to position PacSun for success and growth long after emergence. Notably, the Company has delivered positive comparable store sales in 13 of the past 16 quarters. We look forward to working closely with Gary and the PacSun team to build a stronger future while continuing to deliver the compelling product assortment and great shopping experience that has long defined PacSun to customers.” The Company is seeking customary authority from the Bankruptcy Court to continue to make wage and salary payments, continue various benefits for employees and honor certain customer programs, such as benefits earned under its myGSOM REWARDS loyalty program, gift cards and returns on merchandise purchased prior to the bankruptcy filing. Bankruptcy Court approval for those requests is expected within the next few days. As a result, the Company’s salaried and hourly employees should continue to be paid on the normal schedule, and there are expected to be no changes to various employee benefit programs. In addition, customers should not experience any changes in their relationship with PacSun as there are expected to be no changes to the customer loyalty program, warranty programs, return policies or gift card balances.
Guggenheim Securities is acting as investment banker for the Company, Klee, Tuchin, Bogdanoff & Stern LLP is the Company’s legal counsel in connection with the debt restructuring, and RCS Real Estate Advisors is the Company's real estate advisor. FTI Consulting serves as its restructuring advisor. Perella Weinberg Partners is acting as financial advisor for Golden Gate Capital, and Kirkland & Ellis is Golden Gate Capital’s legal counsel. Choate Hall & Stewart LLP is Wells Fargo's legal counsel
This is not Golden Gate’s first such deal. The $15 billion buyout firm bought Eddie Bauer out of bankrupcty in 2009 for $286 million, then sold it for $875 million five years later.
Pacific Sunwear of California (NASDAQ:PSUN): Q4 EPS of -$0.09 in-line.
Revenue of $232.87M (+0.6% Y/Y) beats by $2.76M.
im still long dont worry
If we really have a lot of luck, WE test 1,50-$2 before launch or a few days after launch, and another 2-ADT filing in 2017 not before.Nasrat is a one Big mouth
Probably We test 0,50-0,57c next 60 days
It's not going to happen $5-10 ) maybe $1-1.50 not more
Wow next week big run up "January Effect". easily 0,50c is coming
As of today our focus remains on ELI-200, on filing it by the end of this year and when I say this year I mean our calendar year meaning December of 2015, by the end of December 2015. We will make an announcement once we receive acceptance of the filing by FDA which most likely will be the first or second week of January unless FDA act faster. So we will file once we receive an acceptance from FDA, we will either issue a press release so have conference call, most likely we'll issue a press release.
Epic is working on filing Loxapine and Dantrolene by the end of Q1 of 2016. We are working on beefing up our generic pipeline and you will see that happening more in 2016 and hear more about it in 2016. Fourth our facility upgrades, it is coming along very nicely. We are a DEA control facility we have two vaults presently one for the R&D and one for commercial and we have just finished installing a very large vault in anticipation of the launch for ELI-200.
We have installed a second packaging line and we are very close to finishing the construction so we can start the validation and scale up activity. A small note on that. The current equipment we have our [GLAS60] would be capable of launching initially ELI-200. Once we activate the new facility then we will have the capability to launch multiple products.
The pain killer: A drug company putting profits above patients
http://www.cnbc.com/2015/11/04/
$2 not coming before RS maybe $1-1.30
sep 2014
http://finance.yahoo.com/q/hp?s=ELTP&a=07&b=24&c=2014&d=08&e=12&f=2014&g=d
sep 2013
http://finance.yahoo.com/q/hp?s=ELTP&a=07&b=24&c=2013&d=08&e=12&f=2013&g=d
and sep 2015 pump to 0,29??
THE NEXT hype and hot air IS COMING 2016 or 2017 $ 1,5-2,48
Eltp need 10,000 kilo fluid bed dryer? Not saying it will happen. Just saying it would be
This is the most important thing
eli- 200 will help
probably Eli- 202 launch Q3 or Q4 2017
maybe Eli -201?, but only maybe
NH
we are working with a couple of companies that are very serious about partnering, but we are also looking into the potential of taking the product to the market ourselves.
It’s interesting, one of the CEOs of a genetic company asked me and the Board that if we would give them our product technology, they will start their own brand division for sale, this is how lucrative this market that we are in.
To be on NASDAQ, you have to have fundamentals, so product development is very important. Our product line is our life line. We are still working and developing all opioids, we're working on formulations and have formulations on stability for oxycodone, hydrocodone, oxymorphone, hydromorphone, and morphine sulfate. However, our primary focus is still ELI-200; we cannot loose sight of that.
I think 2017 not before
Update on Other Development Programs
In addition, the Company also reports results from pivotal and pilot bioequivalence studies for ELI-202. The study results from the pivotal study for ELI-202 demonstrated Elite's product, both the lowest strength and the highest strength, were bioequivalent for the opioid to the branded drug based on pharmacokinetic measures including peak concentration (Cmax) and area under the curve (AUC) for opioid blood plasma levels. ELI-202 is combination drug that contains a second drug and the study results for the second drug showed bioequivalence for AUC, but a lower Cmax. No food effect was seen with either drug. The study was a single dose, open label, partially randomized, three-way cross over study in healthy volunteers with 32 subjects under fasted conditions and under fed conditions.
Prior to receiving the complete and final report for this study, Elite initiated a pilot study to understand and address the lower Cmax for the combination drug. Two formulations were dosed in the pilot study and both formulations demonstrated that a repeat bioequivalence study with 32 subjects or more would be expected to be bioequivalent for the measured parameters. The pilot study was a single dose, open label, randomized, three period, crossover study in 8 healthy volunteers per arm under fasted conditions. A repeat bioequivalence study for ELI-202 is scheduled to begin in early October.
The formulations utilized Elite's proprietary pharmacological abuse deterrent technology with the opioid antagonist naltrexone. Levels of sequestration of naltrexone were also evaluated and dosing of Elite's intact formulation resulted in almost no exposure levels to naltrexone (LOQ of 4 pg/mL) and its metabolite 6-ß-naltrexol (LOQ of 10 pg/mL) as intended.
"Our technology continues to perform as expected with positive outcomes," continued Mr. Hakim. "There will be no impact on our target filing for ELI-202 in Q4 2015."
The P3 Eli 200 results do not come before the Rodman and Renshaw Global Investment Conference in New York City on September 9, 2015.
Where is ELI- 201-202 very quiet?
Merck Q1 adj. EPS 85 cents vs 88 cents; consensus 74 cents
• Q1 EPS 33 cents vs 57 cents
• Merck Q1 sales $9.425 bln vs $10.264 bln; consensus $9.055 bln
• Merck narrows and raises full-year adj EPS to $3.35 to $3.48
• Merck sees full-year revenue $38.3 bln to $39.8 bln
Pfizer Q1 revenue $10.9 bln vs. $11.4 bln; consensus $10.8 bln
• Q1 adj. EPS 51 cents vs 57 cents; consensus 49 cents
• Q1 EPS 38 cents vs 36 cents
• Pfizer now sees full-hear adj. EPS $1.32 to $1.47 vs prior $1.37 to $1.52
• Pfizer now sees full-year revenue of $44 bln to $46 bln vs prior $44.5 bln to $46.5 bln
Shares Outstanding (M)
618.41
Next Earnings Announcement
06/30/2015
I hope we see before Oct. 50 Cents
looks like dead money TO Q1-2016
NH
So that's $0.40, $2.10 and $2.75 and that's not future value, that's the present value today. Future value will be more